On August 23rd, Janssen Cilag International NV, a subsidiary of Johnson&Johnson, announced that the European Commission (EC) has approved BALVERSA& reg; (erdafitinib) is a daily oral monotherapy used to treat adult patients with unresectable or metastatic urothelial carcinoma (mUC).